Robert E. Davis, SVP, Chief Scientific Officer at Intra-Cellular Therapies, Inc. (ITCI), sold 899 shares at $13.53 ($12K) on 2018-12-06, disclosed to the SEC on 2018-12-07.
Scheduled sale ($12k) by SVP, Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| ITCI | SELL | 2018-01-05 | $17K | — | Filing → |
| ITCI | SELL | 2017-12-06 | $10K | — | Filing → |